PNTG heads into its Q2 print today with a clear tension between bullish analyst conviction and persistent selling by the company's own chief executive.
The most striking signal ahead of earnings is the insider activity. CEO Brent Guerisoli sold shares twice in early July — roughly 3,159 shares on July 10 at $41.57 and 3,165 shares on July 7 at $40.51 — adding to a pattern of sales that runs back through May and July 2025. Net insider selling over the past 90 days totals approximately $418,000. These are relatively small disposals in dollar terms and carry low significance scores, but the consistency of the CEO's selling into price strength is a notable counterweight to the bullish analyst narrative.
That analyst narrative is genuinely constructive. Truist Securities raised its target to $48 from $42 on July 14, and Wells Fargo lifted to $45 from $41 on July 13 — both maintaining positive ratings ahead of today's release. The consensus mean target is $45, implying roughly 16% upside from the current $38.81 close, after the stock pulled back about 5.5% on the week. The bull case centres on accelerating occupancy — weighted average occupancy rose 270 basis points year-over-year to 82.7% — and a growth profile that stands out even within health care services, with annual sales growth running near 37%. Bears focus on two structural headwinds: the shift toward Medicare Advantage reimbursement, which carries steep discounts, and the integration risk associated with Pennant's largest-ever acquisition. EV/EBITDA sits around 18.5x, which leaves little room for execution slippage.
The options market registers none of this tension. The put/call ratio is almost exactly in line with its 20-day average at 0.55 — a z-score near zero — suggesting options traders are neither hedging aggressively nor leaning bullishly into the print. The borrow market is equally relaxed: availability is extraordinarily loose at 5,530%, with short interest running at just 2% of the free float and a cost to borrow of 0.51%. Short sellers are not pressing a thesis here. Wasatch Advisors meaningfully added to its position in Q2 (up 451,491 shares to 1.87 million), while Van Berkom trimmed by a comparable amount — institutional flows are splitting rather than converging.
History adds one data point worth noting: the last two earnings prints saw the stock jump more than 10% on the day in both cases, with five-day moves of 13% following each. Today's print will test whether the occupancy recovery and top-line momentum can justify targets that have been repeatedly lifted, or whether Medicare Advantage headwinds and acquisition integration costs have begun to erode the margin story that drove those post-earnings moves.
See the live data behind this article on ORTEX.
Open PNTG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
